IgGκ Signal Peptide Enhances the Efficacy of an Influenza Vector Vaccine against Respiratory Syncytial Virus Infection in Mice

Int J Mol Sci. 2023 Jul 14;24(14):11445. doi: 10.3390/ijms241411445.

Abstract

Intranasal vaccination using influenza vectors is a promising approach to developing vaccines against respiratory pathogens due to the activation of the mucosa-associated immune response. However, there is no clear evidence of a vector design that could be considered preferable. To find the optimal structure of an influenza vector with a modified NS genomic segment, we constructed four vector expressing identical transgene sequences inherited from the F protein of the respiratory syncytial virus (RSV). Two vectors were designed aiming at transgene accumulation in the cytosol. Another two were supplemented with an IgGκ signal peptide prior to the transgene for its extracellular delivery. Surprisingly, adding the IgGκ substantially enhanced the T-cell immune response to the CD8 epitope of the transgene. Moreover, this strategy allowed us to obtain a better protection of mice from the RSV challenge after a single intranasal immunization. Protection was achieved without antibodies, mediated by a balanced T-cell immune response including the formation of the RSV specific effector CD8+ IFNγ+/IL10+-producing cells and the accumulation of Treg cells preventing immunopathology in the lungs of infected mice. In addition to the presented method for optimizing the influenza vector, our results highlight the possibility of achieving protection against RSV through a respiratory-associated T-cell immune response alone.

Keywords: influenza vector; regulatory T-cells; respiratory syncytial virus; vaccine design.

MeSH terms

  • Animals
  • Antibodies, Viral
  • Humans
  • Influenza Vaccines*
  • Influenza, Human*
  • Mice
  • Mice, Inbred BALB C
  • Respiratory Syncytial Virus Infections*
  • Respiratory Syncytial Virus Vaccines*
  • Respiratory Syncytial Virus, Human* / genetics

Substances

  • Influenza Vaccines
  • Antibodies, Viral
  • Respiratory Syncytial Virus Vaccines